“…Despite several significant advancements in targeting CDKs as novel approaches and promising treatment options against TNBC (Figure B,C; compound 1 – 6 − ), there remains a shortage of CDK9 modulators specifically designed for TNBC treatment, and most of these inhibitors either exhibit only moderate potency or target other subtypes of CDKs (especially CDK2, a cell cycle-related CDK with 40% sequence identity to CDK9). − For example, dinaciclib (also named SCH727965 or MK-7965), which progressed into three TNBC-related clinical trials (phase 1 or phase 2; ClinicalTrials.gov ID: NCT00732810, NCT01624441, NCT01676753), have similar inhibitory activity against CDK2 and CDK9 (IC 50 = 1 and 4 nM, respectively); fadraciclib (CYC065), being tested in an ongoing clinical trial on advanced solid tumors, including TNBC (phase 1/2; ClinicalTrials.gov ID: NCT04983810), also targets both CDK2 and CDK9 (IC 50 = 5 and 26 nM, respectively) . Indeed, off-target inhibition might result in side effects and unexpected toxicity, thereby narrowing the therapeutic window and compromising the potential for developing targeted therapeutics; principally, the development of selective inhibitors offers various benefits, including providing specific insight into the mechanism of action, refining patient selection criteria, and facilitating the establishment of a specific therapeutic window .…”